Issues

Gene expression profiles in patients of African ancestry with triple-negative breast cancer indicate differences in normal breast tissue as well as in the tumor-associated immunologic profiles, supporting the potential differences in clinical outcomes between race groups.

Genetic ancestry inference in a clinical pan-cancer cohort of 45,157 patients enabled discovery of ancestry-specific differences in the frequency of somatic features and the prevalence of clinically actionable alterations.

An artificial intelligence classifier trained to distinguish the developmental profiles of different tumor types is applied to cancers of unknown primary, revealing diagnosis for each case.

Proteogenomic analyses of triple-negative breast cancer samples from a neoadjuvant carboplatin/docetaxel chemotherapy trial identified LIG1 loss as a biomarker for carboplatin-selective resistance, chromosomal instability, and disease progression.

Spatial and transcriptomic analysis of a large cohort of human lung tumors uncovers two cancer-associated fibroblast populations and their matrix expression profiles associated with T-cell exclusion in human non–small cell lung carcinoma.

Single-cell and spatial profiling of tumor-infiltrating B and plasma cells in early-stage lung adenocarcinoma (LUAD) highlights previously unappreciated roles of these cells in the LUAD ecosystem and immunotherapy response.

CRCD2 was developed as a first-in-class, small-molecule NT5C2 nucleotidase inhibitor, which enhances the efficacy of thiopurine therapy and overcomes resistance in relapsed acute lymphoblastic leukemia.

Resistance of EGFR-mutant lung cancers to EGFR inhibitors can occur through engagement of mutation-prone DNA replication activated by GAS6 and AXL upregulation, and blocking this pathway can prevent resistance and offer new treatment strategies.

Small-molecule inhibition of ENL leads to suppression of oncogenic gene expression and blocks the progression of MLL-rearranged and NPM1-mutated acute myeloid leukemia (AML), demonstrating ENL as a promising therapeutic target for AML subsets.